<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05087641</url>
  </required_header>
  <id_info>
    <org_study_id>IAB1-CIP</org_study_id>
    <nct_id>NCT05087641</nct_id>
  </id_info>
  <brief_title>A Multicenter, Prospective Trial of the IAB in Adults Suffering From COPD/Emphysema</brief_title>
  <acronym>IAB-1</acronym>
  <official_title>A Multicenter, Prospective Trial of the IAB in Adults Suffering From COPD/Emphysema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pulmair Medical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pulmair Medical, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Pulmair Implantable Artificial Bronchus (IAB) is a device intended for implantation into&#xD;
      the diseased bronchi of emphysema patients. The IAB is indicated for bronchoscopic treatment&#xD;
      of adults with Chronic Obstructive Pulmonary Disease (COPD)/emphysema to relieve&#xD;
      hyperinflation and allow bidirectional ventilation of the affected lobes.&#xD;
&#xD;
      The objective of this trial is to demonstrate a suitable benefit/risk profile to support a&#xD;
      subsequent trial of the safety and effectiveness of the IAB to achieve its intended purpose.&#xD;
&#xD;
      The trial will enroll 24 subjects implanted with IAB(s), at no more than three study centers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">March 2025</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This is an open-label (unblinded), multicenter, prospective trial of the Implantable Artificial Bronchus (IAB) in adults suffering from COPD/emphysema. There is no control group or comparator.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety - Incidence of respiratory serious adverse events (SAEs)</measure>
    <time_frame>From baseline to 90 days post implant (for endpoint evaluation)</time_frame>
    <description>The primary endpoint is the occurrence of respiratory SAEs:&#xD;
Acute asthma/bronchospasm requiring intensive/critical care unit admission&#xD;
Acute COPD exacerbation (is acute onset, life-threatening, requires hospitalization)&#xD;
Airway injury from IAB placement/migration/airway stenosis requiring surgical intervention&#xD;
Death from procedure/IAB&#xD;
Massive hemoptysis (est. &gt;100 ml in 24hr requiring transfusion, surgery, or arterial embolization) from procedure/IAB&#xD;
Pneumonia in treated lobe requiring hospitaliz., IV antibiotics, IAB removal&#xD;
Pneumonia NOT in treated lobe (is life-threatening, acute onset, requires hospitaliz. &amp; IV antibiotics)&#xD;
Pneumothorax requiring surgery&#xD;
Tension pneumothorax (is life-threatening, acute onset, requires hospitaliz. &amp; treatment)&#xD;
Respiratory failure requiring mechanical ventilatory support &gt;24hr&#xD;
A thoracic SAE composite, based on number of subjects experiencing a thoracic SAE, will also be calculated and tabulated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety - Incidence of other serious adverse device effects (SADEs)</measure>
    <time_frame>From baseline to 90 days post implant (for endpoint evaluation)</time_frame>
    <description>All other SADEs are a secondary endpoint, made from the accumulation of adverse events (AEs) to be recorded as they occur regardless of the follow-up schedule.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy - Residual Volume (RV), absolute change</measure>
    <time_frame>From baseline to 90 days post implant (for endpoint evaluation)</time_frame>
    <description>Absolute change in Residual Volume (RV), at both inspiratory and end expiratory levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy - Residual Volume (RV), percent change</measure>
    <time_frame>From baseline to 90 days post implant (for endpoint evaluation)</time_frame>
    <description>Percent change in RV (% predicted), at both inspiratory and end expiratory levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy - Forced Expiratory Volume in one second (FEV1), absolute change</measure>
    <time_frame>From baseline to 90 days post implant (for endpoint evaluation)</time_frame>
    <description>Absolute change in FEV1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy - Forced Expiratory Volume in one second (FEV1), percentage change</measure>
    <time_frame>From baseline to 90 days post implant (for endpoint evaluation)</time_frame>
    <description>Percentage change in FEV1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy - Six-Minute Walk Distance (6MWD), absolute change</measure>
    <time_frame>From baseline to 90 days post implant (for endpoint evaluation)</time_frame>
    <description>Absolute change in 6MWD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy - Six-Minute Walk Distance (6MWD), percent change</measure>
    <time_frame>From baseline to 90 days post implant (for endpoint evaluation)</time_frame>
    <description>Percent change in 6MWD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy - Modified Medical Research Council (mMRC) dyspnea score, absolute change</measure>
    <time_frame>From baseline to 90 days post implant (for endpoint evaluation)</time_frame>
    <description>Absolute change in mMRC dyspnea score. Scores range from 0-4, with a decrease in score representing improved perception of disability attributable to dyspnea.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy - St. George's Respiratory Questionnaire (SGRQ) total score, absolute change</measure>
    <time_frame>From baseline to 90 days post implant (for endpoint evaluation)</time_frame>
    <description>Absolute change in SGRQ total score. Scores range from 0-100, with a decrease in score representing overall improvement in health, daily life, and perceived well-being.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy - St. George's Respiratory Questionnaire (SGRQ), percent change</measure>
    <time_frame>From baseline to 90 days post implant (for endpoint evaluation)</time_frame>
    <description>Percent change in SGRQ</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy - COPD Assessment Test (CAT), absolute change</measure>
    <time_frame>From baseline to 90 days post implant (for endpoint evaluation)</time_frame>
    <description>Absolute changes in CAT. Scores range from 0-40, with a decrease in score representing decreased impact of cough, sputum, dyspnea, and chest tightness on overall health status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy - COPD Assessment Test (CAT) Total Score, percent change</measure>
    <time_frame>From baseline to 90 days post implant (for endpoint evaluation)</time_frame>
    <description>Percent change in CAT Total Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy - European Quality of Life, 5-Dimensional Test (EQ-5D) Summary Index, absolute change</measure>
    <time_frame>From baseline to 90 days post implant (for endpoint evaluation)</time_frame>
    <description>Absolute change in EQ-5D Summary Index. Index values range from 0-1, with a decrease in index value indicating an improvement in health-related quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy - European Quality of Life, 5-Dimensional Test (EQ-5D) Summary Index, percent change</measure>
    <time_frame>From baseline to 90 days post implant (for endpoint evaluation)</time_frame>
    <description>Percent change in EQ-5D Summary Index</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Emphysema</condition>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>IAB System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be treated with IAB(s)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>IAB System</intervention_name>
    <description>Bronchoscopic implantation of one or multiple IABs</description>
    <arm_group_label>IAB System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed Informed Consent&#xD;
&#xD;
          2. Diagnosis of COPD/emphysema&#xD;
&#xD;
          3. Age 40 to 75 years&#xD;
&#xD;
          4. Body Mass Index (BMI) less than 30 kg/m2&#xD;
&#xD;
          5. 6-minute walk Distance between 100 meters and 500 meters at baseline exam&#xD;
&#xD;
          6. Stable disease with less than 10 mg prednisone (or equivalent) daily&#xD;
&#xD;
          7. Non-smoking for 4 months prior to screening interview&#xD;
&#xD;
          8. FEV1 between 15% and 50% of predicted value at baseline exam&#xD;
&#xD;
          9. FEV1/Forced Vital Capacity (FVC) &lt; 70%&#xD;
&#xD;
         10. RV &gt; 175%&#xD;
&#xD;
         11. mMRC score â‰¥ 2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Currently participating in another clinical study&#xD;
&#xD;
          2. Women of child-bearing potential&#xD;
&#xD;
          3. More than 2 COPD exacerbation episodes requiring hospitalization in the last year at&#xD;
             screening&#xD;
&#xD;
          4. Any COPD exacerbations within 6 weeks of planned intervention&#xD;
&#xD;
          5. Two or more instances of pneumonia episodes in the last year at screening&#xD;
&#xD;
          6. Clinically significant mucus production or chronic bronchitis&#xD;
&#xD;
          7. Myocardial Infarction or unstable / uncontrolled congestive heart failure within 6&#xD;
             months of screening&#xD;
&#xD;
          8. Prior lung transplant, Lung Volume Reduction Surgery (LVRS), bullectomy or lobectomy&#xD;
&#xD;
          9. Clinically significant bronchiectasis&#xD;
&#xD;
         10. Unable to safely discontinue anti-coagulants or platelet activity inhibitors for 7&#xD;
             days&#xD;
&#xD;
         11. Uncontrolled pulmonary hypertension (systolic pulmonary arterial pressure &gt; 45 mm Hg)&#xD;
             or evidence or history of cor pulmonale as determined by recent echocardiogram&#xD;
             (completed within the last 3 months prior to screening visit)&#xD;
&#xD;
         12. Suspected pulmonary nodule or lung cancer&#xD;
&#xD;
         13. High Resolution Computed Tomography (HRCT) collected per CT scanning protocol within&#xD;
             the last 6 months of screening date and evaluated by clinical site personnel using 3D&#xD;
             segmentation software shows:&#xD;
&#xD;
               1. Large bullae encompassing greater than 30% of either lung&#xD;
&#xD;
               2. Insufficient landmarks to evaluate the CT study using the software as it is&#xD;
                  intended&#xD;
&#xD;
               3. All lobes are less than 25% parenchyma diseased (&lt; -950 HU)&#xD;
&#xD;
         14. Any cardiac comorbidity which the PI believes would compromise the safety of the&#xD;
             patient after an IAB implant&#xD;
&#xD;
         15. Total Lung Capacity (TLC) &lt; 100% predicted at screening&#xD;
&#xD;
         16. Diffusing Capacity of Carbon Monoxide (DLCO) &lt; 15% or &gt; 50% of predicted value at&#xD;
             screening&#xD;
&#xD;
         17. Partial pressure of carbon dioxide (PaCO2) &gt; 50 mm Hg or Denver scale greater than 55&#xD;
             mm Hg on room air at screening&#xD;
&#xD;
         18. Partial pressure of oxygen (PaO2) &lt; 45 mm Hg or Denver scale less than 30 mm Hg on&#xD;
             room air at screening&#xD;
&#xD;
         19. Plasma cotinine level &gt; 13.7 ng/ml or carboxyhemoglobin (arterial or ear lobe&#xD;
             capillary) &gt; 2.5% at screening&#xD;
&#xD;
         20. Any other conditions, which, in the opinion of the Investigator, would make the&#xD;
             patient unsuitable for inclusion, or could interfere with the patient participating in&#xD;
             or completing the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dirk-Jan Slebos, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center Groningen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jacquelyn Ferguson</last_name>
    <phone>+1 (858) 369-0000</phone>
    <email>jferguson@pulmair.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital de Clinicas de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <zip>CEP 90035-003</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <investigator>
      <last_name>Hugo Goulart de Oliveira, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thoraxklinik, University of Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>D-69126</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Germany</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 28, 2021</study_first_submitted>
  <study_first_submitted_qc>October 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 21, 2021</study_first_posted>
  <last_update_submitted>October 8, 2021</last_update_submitted>
  <last_update_submitted_qc>October 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bronchoscopic Lung Volume Reduction (BLVR)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Pulmonary Emphysema</mesh_term>
    <mesh_term>Emphysema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

